Finance

Lists
9926:HKG
Akeso Inc
91,30 HKD
+0,94%
(+0,85) 1D
16-окт., 16:08:14 GMT+8  ·   HKD
All symbols
SymbolPriceChange% Change
Generating top insights for 9926...
Open
92,15 HKD
High
95,30 HKD
Low
90,15 HKD
Mkt. cap
84,10 млд
Avg. vol.
10,45 млн
Volume
11,09 млн
52-wk high
156,00 HKD
52-wk low
80,20 HKD
EPS
-1,24 HKD
No. of employees
4 миң
Open
92,15 HKD
High
95,30 HKD
Low
90,15 HKD
Mkt. cap
84,10 млд
Avg. vol.
10,45 млн
Volume
11,09 млн
52-wk high
156,00 HKD
52-wk low
80,20 HKD
EPS
-1,24 HKD
No. of employees
4 миң
News stories
From web sources and news partners
Profile
Akeso, Inc is a publicly listed Chinese biopharmaceutical company that is headquartered in Zhongshan, Guangdong. It is best known for developing Ivonescimab, a cancer treatment antibody. Wikipedia
About Akeso Inc
CEOMichelle Xia | Michelle Xia
Employees4,08 миң
Founded2012-ж., 19-мар.
Headquarters-
Sector-
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
822,37 млн
822,37 млн
902,84 млн
902,84 млн
Cost of goods sold
191,35 млн
191,35 млн
264,27 млн
264,27 млн
Cost of revenue
191,35 млн
191,35 млн
264,27 млн
264,27 млн
Research and development expenses
421,91 млн
421,91 млн
391,66 млн
391,66 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
464,36 млн
464,36 млн
477,58 млн
477,58 млн
Operating expense
883,23 млн
883,23 млн
926,32 млн
926,32 млн
Total operating expenses
1,07 млд
1,07 млд
1,19 млд
1,19 млд
Operating income
-252,21 млн
-252,21 млн
-287,75 млн
-287,75 млн
Other non operating income
29,10 млн
29,10 млн
24,64 млн
24,64 млн
EBT including unusual items
-276,45 млн
-276,45 млн
-221,95 млн
-221,95 млн
EBT excluding unusual items
-276,19 млн
-276,19 млн
-226,43 млн
-226,43 млн
Income tax expense
-192,50 миң
-192,50 миң
1,68 млн
1,68 млн
Effective tax rate
0,07%
0,07%
-0,75%
-0,75%
Other operating expenses
-3,04 млн
-3,04 млн
57,08 млн
57,08 млн
Net income
-271,47 млн
-271,47 млн
-212,11 млн
-212,11 млн
Net profit margin
-33,01%
-33,01%
-23,49%
-23,49%
Earnings per share
-
-
-
-
Interest and investment income
84,42 млн
84,42 млн
74,56 млн
74,56 млн
Interest expense
-33,81 млн
-33,81 млн
-31,66 млн
-31,66 млн
Net interest expenses
50,61 млн
50,61 млн
42,90 млн
42,90 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-187,68 млн
-187,68 млн
-210,51 млн
-210,51 млн
Gain or loss from assets sale
-1,00 миң
-1,00 миң
-
-
AI content may include mistakes. Learn more
Google колдонмолору